Search

Your search keyword '"LORDA MAYAYO, Saray"' showing total 3 results
Start Over Author "LORDA MAYAYO, Saray"
3 results on '"LORDA MAYAYO, Saray"'

1. Data Supplement from CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA

Author

Riccardo, Federica, primary, Iussich, Selina, primary, Maniscalco, Lorella, primary, Lorda Mayayo, Saray, primary, La Rosa, Giuseppe, primary, Arigoni, Maddalena, primary, De Maria, Raffaella, primary, Gattino, Francesca, primary, Lanzardo, Stefania, primary, Lardone, Elena, primary, Martano, Marina, primary, Morello, Emanuela, primary, Prestigio, Simone, primary, Fiore, Alessandra, primary, Quaglino, Elena, primary, Zabarino, Sara, primary, Ferrone, Soldano, primary, Buracco, Paolo, primary, and Cavallo, Federica, primary

Published
2023
Full Text
View/download PDF

2. Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination

Author

Piras, Lisa Adele, Riccardo, Federica, Iussich, Selina, Maniscalco, Lorella, Gattino, Francesca, Martano, Marina, Morello, Emanuela Maria, LORDA MAYAYO, Saray, Rolih, Valeria, Garavaglia, F., DE MARIA, Raffaella, Lardone, Elena, Collivignarelli, F., Mignacca, D., Giacobino, D., Ferrone, S., Cavallo, Federica, and Buracco, Paolo

Subjects
Male, CSPG4, comparative oncology, canine oral malignant melanoma, adjuvant immunotherapy, DNA electroporation, Adjuvants, Immunologic, Animals, Cancer Vaccines, Chondroitin Sulfate Proteoglycans, Combined Modality Therapy, Dog Diseases, Dogs, Female, Melanoma, Mouth Neoplasms, Article, Immunologic, canine oral malignant melanoma, adjuvant immunotherapy, CSPG4, DNA electroporation, comparative oncology, Adjuvants
Abstract

Reported post-surgery 1-year survival rate for oral canine malignant melanoma (cMM) is around 30%; novel treatments are needed as the role of adjuvant chemotherapy is unclear. This prospective study regards adjuvant electrovaccination with human chondroitin sulfate proteoglycan-4 (hCSPG4)-encoded plasmid in 23 dogs with resected II/III-staged CSPG4-positive oral cMM compared with 19 dogs with resected only II/III-staged CSPG4-positive oral cMM. Vaccination resulted in 6-, 12-, 18- and 24-month survival rate of 95.6, 73.9, 47.8 and 30.4%, respectively [median survival time (MST) 684 days, range 78–1694, 8 of 23 dogs alive] and 6-, 12-, 18- and 24-month disease-free interval (DFI) rate of 82.6, 47.8, 26.1 and 17.4%, respectively (DFI 477 days, range 50–1694). Non-vaccinated dogs showed 6-, 12-, 18- and 24-month survival rate of 63.2, 26.3, 15.8 and 5.3%, respectively (MST 200 days, range 75–1507, 1 of 19 dogs alive) and 6-, 12-, 18- and 24-month DFI rate of 52.6, 26.3, 10.5 and 5.3%, respectively (DFI 180 days, range 38–1250). Overall survival and DFI of vaccinated dogs was longer in those

Published
2017

3. CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA

Author

Riccardo, Federica, primary, Iussich, Selina, additional, Maniscalco, Lorella, additional, Lorda Mayayo, Saray, additional, La Rosa, Giuseppe, additional, Arigoni, Maddalena, additional, De Maria, Raffaella, additional, Gattino, Francesca, additional, Lanzardo, Stefania, additional, Lardone, Elena, additional, Martano, Marina, additional, Morello, Emanuela, additional, Prestigio, Simone, additional, Fiore, Alessandra, additional, Quaglino, Elena, additional, Zabarino, Sara, additional, Ferrone, Soldano, additional, Buracco, Paolo, additional, and Cavallo, Federica, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results